We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.